ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

8-MOP
Pigmentation disorders
Psoriasis
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

8-MOP Rx

Generic Name and Formulations:
Methoxsalen 10mg; hard gel caps.

Company:
Valeant Pharmaceuticals, Inc

Therapeutic Use:

Indications for 8-MOP:

Repigmentation of idiopathic vitiligo.

Adult:

Give only in conjunction with a schedule of controlled doses of long wave UV radiation. Do not sunbathe during the 24hr period prior to methoxsalen ingestion; avoid sun exposure for at least 8hrs after and do not sunbathe for 48hrs after. Wear UVA absorbing wrap-around sunglasses for 24hrs after. Apply sunscreen if sun exposure unavoidable. 20mg in one dose taken with food or milk 2–4 hours before UV light exposure; max 0.6mg/kg. See literature for UVA exposure schedules.

Children:

Not recommended.

Contraindications:

Idiosyncratic reactions to psoralen compounds. History of light sensitive disease states (eg, lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, albinism). Melanoma or history of. Invasive squamous cell carcinomas. Aphakia.

Warnings/Precautions:

To be used only be physicians with special training in photochemotherapy. Do not use interchangeably with Oxsoralen-Ultra. Increased risk of ocular damage (eg, cataracts), aging of the skin, and skin cancer; monitor. Basal cell carcinoma. Previous radiation or aresenic therapy. Hepatic insufficiency. Cardiovascular disease. Perform ophthalmologic exam prior to start of therapy and then yearly. Obtain CBC, anti-nuclear antibodies, LFTs, creatinine, BUN prior to therapy, then every 6–12 months. Elderly. Pregnancy (Cat.C). Nursing mothers.

Interactions:

Caution with concomitant photosensitizing agents (eg, anthralin, coal tar, griseofulvin, phenothiazines, nalidixic acid, fluoroquinolones, halogenated salicylanilides, sulfonamides, tetracyclines, thiazides, certain organic staining dyes).

Pharmacological Class:

Psoralen.

Adverse Reactions:

Nausea, nervousness, insomnia, depression; combined methoxsalen/UVA therapy: pruritus, erythema, edema, dizziness, headache, malaise, hypopigmentation, vesiculation, bullae formation, rash, herpes simplex, miliaria, urticaria, folliculitis, cutaneous tenderness, leg cramps, hypotension, extension of psoriasis.

How Supplied:

Caps—50

Indications for 8-MOP:

Symptomatic control of severe, recalcitrant, disabling psoriasis not adequately responsive to other forms of therapy and when the diagnosis has been supported by biopsy.

Adult:

Give only in conjunction with a schedule of controlled doses of long wave UV radiation. Do not sunbathe during the 24hr period prior to methoxsalen ingestion; avoid sun exposure for at least 8hrs after and do not sunbathe for 48hrs after. Wear UVA absorbing wrap-around sunglasses for 24hrs after. Apply sunscreen if sun exposure unavoidable; do not apply to areas affected by psoriasis until after UVA treatment. Take 2 hours before UVA exposure with food or milk. <30kg: 10mg. 30–50kg: 20mg. 51–65kg: 30mg. 66–80kg: 40mg. 81–90kg: 50mg. 91–115kg: 60mg. >115kg: 70mg. See literature for UVA exposure schedules.

Children:

Not recommended.

Contraindications:

Idiosyncratic reactions to psoralen compounds. History of light sensitive disease states (eg, lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, albinism). Melanoma or history of. Invasive squamous cell carcinomas. Aphakia.

Warnings/Precautions:

To be used only be physicians with special training in photochemotherapy. Do not use interchangeably with Oxsoralen-Ultra. Increased risk of ocular damage (eg, cataracts), aging of the skin, and skin cancer; monitor. Basal cell carcinoma. Previous radiation or aresenic therapy. Hepatic insufficiency. Cardiovascular disease. Perform ophthalmologic exam prior to start of therapy and then yearly. Obtain CBC, anti-nuclear antibodies, LFTs, creatinine, BUN prior to therapy, then every 6–12 months. Elderly. Pregnancy (Cat.C). Nursing mothers.

Interactions:

Caution with concomitant photosensitizing agents (eg, anthralin, coal tar, griseofulvin, phenothiazines, nalidixic acid, fluoroquinolones, halogenated salicylanilides, sulfonamides, tetracyclines, thiazides, certain organic staining dyes).

Pharmacological Class:

Psoralen.

Adverse Reactions:

Nausea, nervousness, insomnia, depression; combined methoxsalen/UVA therapy: pruritus, erythema, edema, dizziness, headache, malaise, hypopigmentation, vesiculation, bullae formation, rash, herpes simplex, miliaria, urticaria, folliculitis, cutaneous tenderness, leg cramps, hypotension, extension of psoriasis.

How Supplied:

Caps—50

Sign Up for Free e-newsletters